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Zika virus was first identified in Africa in 1947, where it 
continues to cause regular outbreaks in sub-Saharan 
Africa but with very few clinical cases. In 1966, a distinct 
Asian lineage was found in Malaysia,1 but human disease 
remained uncommon in the Asia–Pacific region, despite 
serological surveys suggesting widespread occurrence 
of subclinical infections. The first recognised epidemic 
happened on the Micronesian island of Yap in 2007. 
It then spread across the Pacific to Easter Island and in 
2015–16, it emerged in South and Central America and 
the Caribbean.2 The virus is maintained primarily in a 
cycle between humans and Aedes aegypti mosquitoes.
The symptomatic illness is nearly always a mild, 
self-limiting illness with fever, rash, joint pain, and 
conjunctivitis. Normally this would not have attracted 
the attention of the world in the way that Zika has. 
Reports linking Zika with microcephaly and fetal deaths 
in the Americas, and with serious neurological disease, 
particularly Guillain-Barré syndrome, have led to the 
WHO declaring the outbreak a global emergency.3 In The 
Lancet, Van-Mai Cao-Lormeau and colleagues present 
the first strong evidence that Zika virus can cause 
Guillain-Barré syndrome.4
Guillain-Barré syndrome is a serious immune-
mediated illness manifesting as progressive paralysis 
over 1–3 weeks, with a 5% death rate and up to 20% 
left with a significant disability.5 Although it [A: What 
are you referring to here? Cases? Reports?] has been 
infrequent, several flaviviruses have been found to 
trigger Guillain-Barré syndrome, including Japanese 
encephalitis virus, West Nile virus, dengue viruses,6 and 
the live-attenuated yellow fever vaccine. So it should 
not have been a surprise when a tentative Zika-induced 
case of Guillain-Barré syndrome was reported from 
French Polynesia in 2013.7
This new case-control study4 is based on 42 notified 
cases of Guillain-Barré syndrome in French Polynesia 
during their 2013–14 [A: Correct change to 2013–14?] 
Zika epidemic. Unfortunately, the patients were no 
longer viraemic at the time of presentation and urine 
samples, which remain PCR positive for longer,8 were 
not available for testing. So the authors faced major 
challenges in proving recent Zika virus infection in 
their cases. They relied on serological criteria for 
diagnosis, a tricky procedure when there is a high 
background of dengue infection in this population. 
Flavivirus antibodies are widely cross-reactive across the 
species, and there are also cross-species immune recall 
phenomena that can lead to spurious early antibody 
responses when the person has had another flavivirus 
infection in the past. In fact, only one of the 42 cases 
showed the standard criterion of neutralisation titres 
to Zika virus that are four-fold or higher than the titre 
to the dengue viruses. Because serum samples were 
collected weeks after the initial febrile illness, the 
investigators were unable to test for rising antibody 
concentrations that might have helped confirm recent 
Zika infection. The authors instead had to rely on the 
detection of IgM to Zika in the absence of dengue IgM 
(to show it was not a cross-reaction; 39 [93%] patients 
[A: Data added correct?]) or the higher rate of Zika 
neutralising antibodies in patients with Guillain-Barré 
syndrome compared with the matched non-febrile 
illness control group (42 [100%] of 42 patients in 
Guillain-Barré syndrome group vs 54 [56%] of 98 in 
control group] [A: Data added correct?]), contrasting 
with the similar dengue antibody levels across the two 
groups. However, none of this is perfect, so although 
it is very likely that these patients had been recently 
infected with Zika virus, it is possible that the disease, 
at least in some of them, was due to dengue or might 
possibly have been unrelated to flavivirus infection.
The cases fitted the acute motor axonal neuropathy 
(AMAN) phenotype of Guillain-Barré syndrome,7 
which has been postulated to be due to antiglycolipid 
antibodies.4 However, the researchers did not find 
the expected pattern of antibodies, nor did they find 
evidence for molecular mimicry between Zika virus 
antigens and the anti-glycolipid antibodies that 
might induce an autoimmune response. Therefore, 
they postulate different methods of pathogenesis, 
including direct viral effects. We clearly need a better 
understanding of the pathogenesis of this disease.
The study7 calculated a Guillain-Barré syndrome rate 
of 0·24 per 1000 Zika virus infections, which could 
translate into large numbers of cases as the epidemic 
Zika virus and Guillain-Barré syndrome: another viral cause 
to add to the list
Published Online 








Embargo: [add date when known]
Comment
2 www.thelancet.com   Published online February 29, 2016   http://dx.doi.org/10.1016/PII
continues. Brazil, El Salvador, Columbia, and Venezuela 
have reported increases in cases of Guillain-Barré 
syndrome coincident with their Zika virus epidemics, 
including three PCR-confirmed infections.9,10 However, 
it is important that these increases are verified to ensure 
they are not to the result of enhanced reporting rather 
than a genuine change.
Because 88% of the cases reported in Cao-Lormeau 
and colleagues’ study reported a preceding clinical illness 
and because Zika is said to be symptomatic in only 20% 
of cases based on the Yap outbreak,11 asymptomatic 
infection might pose a much lower risk of Guillain-Barré 
syndrome than does symptomatic disease. However, 
that is assuming that the case-to-infection ratio in the 
current outbreak is the same as that in the Yap outbreak, 
which is also yet to be confirmed.
Reassuringly, the investigators they did not find any 
evidence that previous dengue infection enhanced 
the severity of disease,7 which could substantially 
have increased the threat in areas of regular dengue 
activity. A little caution should be taken because the 
data are still scarce [A: Edit to scarce from limited ok?] 
and we do not know whether the current [A: Zika?] 
virus is identical to earlier ones [A: that in previous 
outbreaks?], whether it will behave exactly the same 
in a different population with a different genetic and 
immunity background, or whether a cofactor or co-
infection is responsible.
Suffice to say Zika virus can be added to our list of 
viruses that can cause Guillain-Barré syndrome, and 
investigation [A: of?] should include this [A: Zika?] if 
there is a possibility of infection. Whether Zika will be 
proven to be a bigger Guillain-Barré syndrome threat 
[A: Please confirm meaning here] than its various 
flavivirus cousins remains to be determined.
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